标题
Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases
作者
关键词
-
出版物
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 288, Issue 39, Pages 27960-27971
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2013-08-03
DOI
10.1074/jbc.m113.485979
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- New β-lactam-β-lactamase inhibitor combinations in clinical development
- (2013) David M. Shlaes Annals of the New York Academy of Sciences
- Proliferation and significance of clinically relevant β-lactamases
- (2013) Karen Bush Annals of the New York Academy of Sciences
- Structural Insight into Potent Broad-Spectrum Inhibition with Reversible Recyclization Mechanism: Avibactam in Complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-Lactamases
- (2013) Sushmita D. Lahiri et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination
- (2013) George G. Zhanel et al. DRUGS
- “Stormy waters ahead”: global emergence of carbapenemases
- (2013) Gopi Patel et al. Frontiers in Microbiology
- In VitroAntibacterial Activity of the Ceftazidime-Avibactam (NXL104) Combination against Pseudomonas aeruginosa Clinical Isolates
- (2012) Premavathy Levasseur et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276
- (2012) Krisztina M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- NXL104 Irreversibly Inhibits the β-Lactamase from Mycobacterium tuberculosis
- (2012) Hua Xu et al. BIOCHEMISTRY
- Improving known classes of antibiotics: an optimistic approach for the future
- (2012) Karen Bush CURRENT OPINION IN PHARMACOLOGY
- Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole
- (2012) L.J. Dubreuil et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Avibactam is a covalent, reversible, non- -lactam -lactamase inhibitor
- (2012) D. E. Ehmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploring the Inhibition of CTX-M-9 by β-Lactamase Inhibitors and Carbapenems
- (2011) Christopher R. Bethel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)
- (2011) A. Walkty et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
- (2011) N. Gupta et al. CLINICAL INFECTIOUS DISEASES
- Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors
- (2011) Ken Coleman CURRENT OPINION IN MICROBIOLOGY
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
- (2011) Z. Aktaş et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evolution to carbapenem-hydrolyzing activity in noncarbapenemase class D -lactamase OXA-10 by rational protein design
- (2011) F. De Luca et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exploring sequence requirements for C3/C4carboxylate recognition in thePseudomonas aeruginosacephalosporinase: Insights into plasticity of the AmpC β-lactamase
- (2011) Sarah M. Drawz et al. PROTEIN SCIENCE
- Epidemiological Expansion, Structural Studies, and Clinical Challenges of New β-Lactamases from Gram-Negative Bacteria
- (2010) Karen Bush et al. Annual Review of Microbiology
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae
- (2010) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Three Decades of -Lactamase Inhibitors
- (2010) S. M. Drawz et al. CLINICAL MICROBIOLOGY REVIEWS
- Current Challenges in Antimicrobial Chemotherapy
- (2010) Carine Bebrone et al. DRUGS
- New β-lactam antibiotics and β-lactamase inhibitors
- (2010) Karen Bush et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Inhibitor Resistance in the KPC-2 -Lactamase, a Preeminent Property of This Class A -Lactamase
- (2009) K. M. Papp-Wallace et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Diversity, Epidemiology, and Genetics of Class D -Lactamases
- (2009) L. Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Updated Functional Classification of -Lactamases
- (2009) K. Bush et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive update
- (2009) M. Shahid et al. CRITICAL REVIEWS IN MICROBIOLOGY
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
- (2009) T. Stachyra et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemases
- (2008) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started